Inhibitory effect of toremifene monotherapy or combined with gemcitabine on A549 human lung adenocarcinoma cells

Objective： The aim of this study was to investigate the effect of toremifene on A549 human lung adenocarci- noma cells, and its sensibilization with gemcitabine, so that to provide a new clinical approach for non-small-cell lung cancer （NSCLC）. Methods： A549 cells were seeded into 96-well plates and exposed to different agents （gemcitabine or gemcitabine with toremifene）. The cytotoxicity of each agent was evaluated by MTT, cell cycle and apoptotic rate were detected by flow cytometry （FCM）. Results： 1. By using FCM, we found A549 cells in S and G2/M phases with toremifene decreased but increased in G0/G1 phase. The higher concentration of toremifene, the more decreased was when compared with the control group. 2. FCM showed toremifene＇s apoptosis effect on A549 cells increased with its increasing dose. 3. By MTT, toremifene had no cytotoxic effect on A549 cells at the concentration of 5 or 2.5 pmol/L. The IC5o of gemcitabine to A549 was 34.51 tJmol/L, and the combined group was 13.59 pmol/L. Conclusion： Toremifene could inhibit the growth of A549 human lung adenocarcinoma cells. Toremifene combined with gemcitabine showed significantly remarkable chemotherapy sensibilization on A549 human lung adenocarcinoma cells.     

Imaging assessment of rounded atelectasis: A pictorial essay

Rounded atelectasis is an increasingly recognized but under‐diagnosed and sometimes misdiagnosed pulmonary entity. This pictorial essay will present a broad range of examples of rounded atelectasis across different imaging modalities with inclusion of typical and atypical presentations. These examples will highlight imaging features that allow confident diagnosis and those that warrant further management, such as imaging surveillance, alternate imaging or invasive procedures for histological evaluation.     

卵巢浆液性腺癌肿瘤微环境中CD8~+TILs密度及PD-L1的表达与临床意义

目的:研究卵巢浆液性腺癌肿瘤微环境中CD8~+肿瘤浸润淋巴细胞(TILs)密度及癌细胞程序性死亡配体-1(PD-L1)的表达情况与临床意义。方法:收集2004年7月至2010年12月于上海交通大学医学院附属仁济医院行肿瘤细胞减灭术的116例卵巢浆液性腺癌患者组织标本,免疫组化检测肿瘤组织CD8~+TILs密度及癌细胞PD-L1表达情况;Spearman相关性分析癌细胞PD-L1表达水平与癌巢及间质CD8~+TILs数目的关系;采用乘积极限法进行基于癌巢CD8~+TILs密度及肿瘤细胞PD-L1表达的单因素生存分析。结果:卵巢浆液性腺癌PD-L1高表达的比例为70.69%(82/116)。癌细胞PD-L1表达强度与癌巢内的CD8~+TILs数目呈显著负相关(P=0.024),而与间质内的CD8~+TILs数目无相关性(P=0.117)。癌巢CD8~+TILs高密度组患者的中位生存时间(64月)显著高于低密度组(43月),差异有统计学意义(P0.05);乘积极限法的亚组分析显示肿瘤微环境中癌细胞PD-L1低表达癌巢CD8~+TILs高密度组患者的预后较好。结论:卵巢浆液性腺癌肿瘤微环境中癌巢CD8~+TILs密度及癌细胞PD-L1表达水平与患者预后密切相关,重视肿瘤微环境的免疫分型有助于评估患者预后及筛选合适患者实施抗PD-1/PD-L1免疫治疗。     

Nanomedicine for acute respiratory distress syndrome: The latest application,targeting strategy,and rational design

Acute respiratory distress syndrome (ARDS) is characterized by the severe inflammation and destruction of the lung air–blood barrier, leading to irreversible and substantial respiratory function damage. Patients with coronavirus disease 2019 (COVID-19) have been encountered with a high risk of ARDS, underscoring the urgency for exploiting effective therapy. However, proper medications for ARDS are still lacking due to poor pharmacokinetics, non-specific side effects, inability to surmount pulmonary barrier, and inadequate management of heterogeneity. The increased lung permeability in the pathological environment of ARDS may contribute to nanoparticle-mediated passive targeting delivery. Nanomedicine has demonstrated unique advantages in solving the dilemma of ARDS drug therapy, which can address the shortcomings and limitations of traditional anti-inflammatory or antioxidant drug treatment. Through passive, active, or physicochemical targeting, nanocarriers can interact with lung epithelium/endothelium and inflammatory cells to reverse abnormal changes and restore homeostasis of the pulmonary environment, thereby showing good therapeutic activity and reduced toxicity. This article reviews the latest applications of nanomedicine in pre-clinical ARDS therapy, highlights the strategies for targeted treatment of lung inflammation, presents the innovative drug delivery systems, and provides inspiration for strengthening the therapeutic effect of nanomedicine-based treatment.     

基于HMMR在肺腺癌组织中表达水平及其对LUAD患者预后影响的生物信息学分析

探讨透明质酸介导的细胞游走受体 （HMMR） 在肺腺癌 （LUAD） 组织中的表达及其对LUAD患者预后的影响，阐明HMMR在LUAD发生发展中的作用。     

和田地区初治肺结核患者低体重营养不良现状及影响因素分析

目的 调查新疆和田地区初治肺结核患者低体重营养不良现状,并分析其影响因素,为临床规范的营养支持提供参考依据。 方法 选取2020年1—5月在新疆和田地区某医院住院的342名初治肺结核患者作为研究对象,采用问卷调查法对其低体重营养不良状况进行调查,用SPSS 20.0软件进行χ²检验,用多因素logistic回归分析低体重营养不良现状及影响因素。 结果 共回收有效问卷342份,其中男174名(50.9%),女168名(49.1%)。在调查对象中,共有162例(47.4%)发生低体重营养不良。多因素logistic回归分析结果显示,年龄≥60岁[OR(95%CI):3.380(1.681～6.793)]、饮酒[OR(95%CI):4.060(1.696～9.719)]、有合并症[OR(95%CI):1.596(1.053～2.901)]是初治肺结核患者低体重营养不良的危险因素,家庭人均月收入≥3 000元[OR(95%CI):0.531(0.215～0.947)]为保护因素。 结论 和田地区初治肺结核患者低体重营养不良发生率较高,年龄、饮酒、合并症、家庭人均月收入是初治肺结核患者低体重营养不良的影响因素,医护人员应重视其营养风险的评估及筛查,早期进行有针对性的营养干预,预防或减缓肺结核患者低体重营养不良的发生发展。     

护理干预对慢性阻塞性肺疾病患者治疗效果及依从性的影响

目的 探讨护理干预对慢性阻塞性肺疾病(COPD)患者治疗效果及治疗依从性的影响.方法 将80例住院治疗的COPD患者随机分为干预组和常规组,各40例.常规组采用常规护理方法.干预组在常规护理的基础上采用护理干预措施.比较两组治疗效果和治疗依从性.结果 两组治疗效果、治疗依从性比较有显著性差异(P<0.05).结论 采用有效的护理干预措施,能有效提高COPD患者治疗效果和治疗依从性.